Submitted by sandy craine on Sat, 02/03/2013 - 3:29pm
"...Three months ago, my PCR result was .07% (or 0.0245% on the IS). It doesn’t take a genius (I wish it literally did take a genius) to see that the results aren’t as good as they were three months ago. However, it’s important to remember that these results are really subjective. They all depend on the sample that they’re testing. In September, we looked at a different sample than we did in December, which was drawn from a different location in the hip. There was going to be a slight dissimilarity anyway. Therefore, a 0.02% (or 0.0055% on IS) differential isn’t particularly alarming. Cognitively, this is all that matters....."more
"...Three months ago, my PCR result was .07% (or 0.0245% on the IS). It doesn’t take a genius (I wish it literally did take a genius) to see that the results aren’t as good as they were three months ago. However, it’s important to remember that these results are really subjective. They all depend on the sample that they’re testing. In September, we looked at a different sample than we did in December, which was drawn from a different location in the hip. There was going to be a slight dissimilarity anyway. Therefore, a 0.02% (or 0.0055% on IS) differential isn’t particularly alarming. Cognitively, this is all that matters....."more
Submitted by sandy craine on Thu, 28/02/2013 - 12:31pm
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
By Jessica Wapner
'A couple of months ago, the FDA approved the latest drug to treat chronic myeloid leukemia (CML). Called ponatinib (brand name Iclusig, made by Ariad), the drug is a third-generation tyrosine kinase inhibitor, the latest in a class of agents founded in 2001 with the approval of imatinib (Gleevec, Novartis). Imatinib, followed by dasatinib and nilotinib, and now ponatinib, are tyrosine kinase inhibitors. These drugs block the activity of a mutant kinase that triggers the growth of white blood cells in an uncontrolled way. By plugging up the site at which the kinase binds with ATP (the energy storehouse of the cell, from which the kinase plucks a single phosphate and then transports that phosphate to the next protein in line on the pathway that leads to white blood cell production), these drugs essentially stop the process that defines CML.
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
By Jessica Wapner
'A couple of months ago, the FDA approved the latest drug to treat chronic myeloid leukemia (CML). Called ponatinib (brand name Iclusig, made by Ariad), the drug is a third-generation tyrosine kinase inhibitor, the latest in a class of agents founded in 2001 with the approval of imatinib (Gleevec, Novartis). Imatinib, followed by dasatinib and nilotinib, and now ponatinib, are tyrosine kinase inhibitors. These drugs block the activity of a mutant kinase that triggers the growth of white blood cells in an uncontrolled way. By plugging up the site at which the kinase binds with ATP (the energy storehouse of the cell, from which the kinase plucks a single phosphate and then transports that phosphate to the next protein in line on the pathway that leads to white blood cell production), these drugs essentially stop the process that defines CML.
Submitted by sandy craine on Wed, 27/02/2013 - 9:29pm
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1, Jeffrey S. Pufnock1,‡, Thomas M. Schmitt1, Natalie Duerkopp1, Ilana M. Roberts1,§, Galina L. Pogosov2, William Y. Ho1,¶, Sebastian Ochsenreither1,||, Matthias Wölfl1,**, Merav Bar2, Jerald P. Radich2, Cassian Yee1,††‡‡ and Philip D. Greenberg1,3,‡‡
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1, Jeffrey S. Pufnock1,‡, Thomas M. Schmitt1, Natalie Duerkopp1, Ilana M. Roberts1,§, Galina L. Pogosov2, William Y. Ho1,¶, Sebastian Ochsenreither1,||, Matthias Wölfl1,**, Merav Bar2, Jerald P. Radich2, Cassian Yee1,††‡‡ and Philip D. Greenberg1,3,‡‡
Submitted by sandy craine on Fri, 22/02/2013 - 9:02pm
'Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD'
Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, and Neil P. Shah1
'Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD'
Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, and Neil P. Shah1
Submitted by sandy craine on Wed, 06/02/2013 - 12:07pm
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1, Lihui Wang2, Christos Paliompeis1, Marco Bua1, Alistair Reid1, Katayoun Rezvani1, Stephen O'Brien3, Richard Clark2, John Goldman1, and David Marin1,
http://bloodjournal.hematologylibrary.org/content/early/2013/02/04/blood-2012-11-466037.abstract?papetoc
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1, Lihui Wang2, Christos Paliompeis1, Marco Bua1, Alistair Reid1, Katayoun Rezvani1, Stephen O'Brien3, Richard Clark2, John Goldman1, and David Marin1,
http://bloodjournal.hematologylibrary.org/content/early/2013/02/04/blood...
Submitted by sandy craine on Mon, 04/02/2013 - 1:58pm
The findings are published in the Dec. 24 online early edition of the Proceedings of the National Academy of Sciences (PNAS).
The findings are published in the Dec. 24 online early edition of the Proceedings of the National Academy of Sciences (PNAS).
Submitted by sandy craine on Sat, 26/01/2013 - 8:10pm
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Submitted by sandy craine on Thu, 24/01/2013 - 11:00am
Funding for new research to improve leukaemia treatment by investigating how cancer cells use hiding places in the body to avoid chemotherapy drugs.
Funding for new research to improve leukaemia treatment by investigating how cancer cells use hiding places in the body to avoid chemotherapy drugs.
Submitted by sandy craine on Tue, 22/01/2013 - 1:50pm
On 17 January 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Bosulif 100 mg and 500 mg film-coated tablets intended for the treatment of chronic myelogenous leukaemia (CML). Bosulif was designated as an orphan medicinal product on 4 August 2010.
On 17 January 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Bosulif 100 mg and 500 mg film-coated tablets intended for the treatment of chronic myelogenous leukaemia (CML). Bosulif was designated as an orphan medicinal product on 4 August 2010.
Submitted by sandy craine on Tue, 08/01/2013 - 11:47am
Evaluation of the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Newcastle University, U.K., on behalf of the U.K. National Cancer Research Institute (NCRI) CML Working Group, today announced an agreement to collaborate on a multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess the impact of switching patients with chronic myeloid leukemia (CML) being treated with a first-line tyrosine kinase inhibitor, upon suboptimal response or treatment failure, to ponatinib. The NCRI expects to begin enrollment in the trial of 1,000 patients at approximately 172 clinical research sites in the U.K. in the second quarter of 2013.
Evaluation of the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Newcastle University, U.K., on behalf of the U.K. National Cancer Research Institute (NCRI) CML Working Group, today announced an agreement to collaborate on a multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess the impact of switching patients with chronic myeloid leukemia (CML) being treated with a first-line tyrosine kinase inhibitor, upon suboptimal response or treatment failure, to ponatinib. The NCRI expects to begin enrollment in the trial of 1,000 patients at approximately 172 clinical research sites in the U.K. in the second quarter of 2013.
Pages
